Table 1 Recent Data About Desloratadine Use in Respiratory Diseases: Clinical Trials and End Points
From: Review of Desloratadine Data Using the ARIA Guidelines
Criteria | Data | End Point |
|---|---|---|
SAR | Pradalier et al. Allergy. 2007;62:1331 (AERONEF) | TSS |
| Â | Kosa L. JACI. 2008;121: S51 (open label) | Nasal, ocular |
| Â | Keith et al. Clin Ther. 2007;121;1151-1155 | Nasal, ocular, respiratory, and overall symptoms |
| Â | Meltzer et al. Ann Allergy Asthma Immunol. | TSS, nasal airflow |
| Â | 2006;96;363-368. | Â |
PAR | Kim et al. Ann Allergy Asthma Immunol. | TSS; PNIF |
| Â | 2006;96:460 (TNSS, PNIF) | Â |
IAR/PER | ACCEPT | Â |
Asthma | Rossi et al. Allergy. 2005; 60:416. | TNSS, asthma symptoms in peds |
Meta-analysis | Canonica et al. Allergy. 2007;62:359. | TSS, nasal airflow |
Peds | Tassinari et al. AAAAI 2006. (SAR/PAR TSS) | SAR, PAR, TSS |
| Â | Rossi et al. Allergy. 2005; 60:416-417 | TNSS, asthma symptoms in peds |
| Â | Dizdar et al. Int J Pediatr Otorhinoloaryngol. 2007;71:843-849 | PRN use in peds |